Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs

References

• Belani C. P., Egorin M. J., Abrams J. S., Hiponi D., Eisenberger M., Aisner J., van Echo D. A. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. Journal of Clinical Oncology 1989; 7: 1896–1902
   PubMedGoogle Scholar
• Bunn P. A. Carboplatin: Current status and future directions. Carboplatin (JM-8), P. A. Bunn, R. Canetta, R. F. Ozols. W. B. Saunders, Philadelphia 1990; 371–392
   Google Scholar
• Calvert A. H., Newell L. A., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddick Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. Journal of Clinical Oncology 1989; 7: 1748–1756
   PubMed Web of Science ®Google Scholar
• Cohen J. D., Robins H. I. Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) cytotoxicity in human leukemia cells in vitro. Cancer Research 1987; 47: 4335–4337
   PubMed Web of Science ®Google Scholar
• Cox D. R., Snell E. J. Analysis of Binary Data, 23rd Edn. Methuen, London 1989; 158–161
   Google Scholar
• Cronau L. H., Mansfield B., Bull J. M. C. Serum creatinine concentration and clearance during whole body hyperthermia under general anesthesia. Anesthesiology 1987; 67: A306
   Google Scholar
• Dahl O. Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity. In Hyperthermia and Oncology. Hyperthermic Potentiation of Chemotherapeutic Agents, M. Urano, E. Douple, 1994; Vol 4: 9–29
   Google Scholar
• Elferink W. J. F., van der Vijgh I., Vermorken J. B., Gall H. E., Pinedo H. M. Pharmacokinetics of carboplatin after IV administration. Cancer Treatment Reports 1987; 71: 1231–1237
   PubMedGoogle Scholar
• Engelhardt R. Hyperthermia and dogs. Recent Results in Cancer Research 1987; 104: 133–203
   Google Scholar
• Gerard H., Egorin M. J., Whitacre M., Van Echo D. A., Aisner J. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum (ii) and whole body hyperthermia. Cancer Chemotherapy and Pharmacology 1983; 11: 162–166
   PubMedGoogle Scholar
• Koeller J. M., Trump D. L., Tutsch K. D., Earhart R. H., Davis T. E., Tormey D. C. Phase I clinical trial and pharmacokinetics of carboplatin (NSC241240) by single monthly 30 minute infusion. Cancer 1986; 57: 222–225
   PubMed Web of Science ®Google Scholar
• Los G., Smals O. A. G., van Vugt M. J. H., van der Vlist, den Englese L., McVie J. G., Pinedo H. M. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Research 1992; 52: 1252–1258
   PubMed Web of Science ®Google Scholar
• Matsushita S., Reynolds R., Urano M. Synergism between alkylating agent and cis-platin with moderate local hyperthermia: the effect of multidrug chemotherapy in an animal system. International Journal of Hyperthermia 1993; 9: 285–296
   PubMed Web of Science ®Google Scholar
• Mella O., Eriksen R., Dahl O., Laerum O. D. Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat. European Journal of Cancer and Clinical Oncology 1987; 23: 365–373
   PubMedGoogle Scholar
• O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33–48
   PubMed Web of Science ®Google Scholar
• Ohno S., Siddick Z. H., Baba H., Stephens L. C., Strebel F. R., Wondergem J., Khokhar A. R., Bull J. M. C. Effect of Carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Research 1991; 51: 2994–3000
   PubMed Web of Science ®Google Scholar
• Page R. L., Riviere J. E., Hoopes P. J., Meyer R. E., Thrall D. E., Dewhirst M. W. Dopamine effects on renal function and cisplatin elimination in dogs undergoing whole body hyperthermia. Proceedings of 8th International Congress of Radiation Research. Edinburgh 1987, Abs
   Google Scholar
• Page R. L., Thrall D. E., Dewhirst M. W., Macy D. W., George S. L., McEntee M. C., Heidner G. L., Novotney C. A., Allen S. A., Withrow S. J., Ogilvie G. K., Gillette E. L. Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. International Journal of Hyperthermia 1991; 7: 559–566
   PubMed Web of Science ®Google Scholar
• Page R. L., Thrall D. E., George S. L., Price G. S., Heidner G. L., McEntee M. C., Novotney C. A., Hauck M. L., Dewhirst M. W. Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumourbearing dogs. International Journal of Hyperthermia 1992; 8: 761–769
   PubMed Web of Science ®Google Scholar
• Riviere J. E., Page R. L., Rogers R. A., Chang S. K., Dewhirst M. W., Thrall D. E. Nonuniform alteration of cis-diamminedichloroplatinum(II) tissue distribution in dogs with whole body hyperthermia. Cancer Research 1990; 50: 2075–2080
   PubMed Web of Science ®Google Scholar
• Robins H. I., Cohen J. D., Schmitt C., Tutsch K. D., Feieraband C., Arzoomanian R., Alberti D., Kuzminsky S., Spriggs D. A. A phase I trial of carboplatin (CBDCA) and whole body hyperthermia (WBH) in cancer patients. Proceedings, 13th North American Hyperthermia Society Meeting. March 7, 1993
   Google Scholar
• Siddik Z. H., Wondergem J., Strebel F., Baba H., Alonso M., Burditt T., Khokhar A. R., Bull J. M. C. Plasma clearances and tissue levels of cisplatin and carboplatin in rats receiving whole body hyperthermia. Proceedings American Association of Cancer Research. 1990; 31: 392
   Google Scholar
• Stone E. A., McLeod D. A., Thrall D. E. Effects of whole body hyperthermia on renal blood flow. Proceedings, 37th annual Radiation Research Society. Seattle, WA 1989, abstr
   Google Scholar
• Storer B. E. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925–937
   PubMed Web of Science ®Google Scholar
• Thrall D. E., Page R. L., Dewhirst M. W., Meyer R. E., Hoopes P. J., Kornegay J. M. Temperature measurements in normal and tumor tissue in dogs undergoing whole body hyperthermia. Cancer Research 1986; 46: 6229–6235
   PubMed Web of Science ®Google Scholar
• Tyczkowska K., Page R. L., Riviere J. E. Determination of carboplatin in canine plasma by liquid chromatography with ultraviolet-visible detection and confirmation by atomic absorption spectroscopy. Journal of Chromatography 1990; 527: 447–453
   PubMedGoogle Scholar
• Wondergem J., Bulger R. E., Strebel F. R., Newman R. A., Travis E. L., Stephens L. C., Bull J. M. C. Effect of cisdiamminedichloroplatinum (II) combined with whole body hyperthermia on renal injury. Cancer Research 1988; 48: 440–446
   PubMed Web of Science ®Google Scholar
• Xu M., Alberts D. S. Potentiation of platinum analogue cytotoxicity by hyperthermia. Cancer Chemotherapy and Pharmacology 1988; 21: 191–196
   PubMed Web of Science ®Google Scholar